|
Jul 5
|
Pharma Stock Roundup: FDA Nod to LLY's Kisunla, SNY's Dupixent Gets EU Nod for COPD
|
|
Jul 5
|
Roche (RHHBY) Receives FDA Nod for Vabysmo Prefilled Syringe
|
|
Jul 5
|
Roche's New Immunotherapy Fails To Show Benefit Over Merck's Blockbuster Keytruda In Lung Cancer Patients
|
|
Jul 5
|
Roche gains FDA approval for Vabysmo prefilled syringe
|
|
Jul 5
|
FDA Approves Genentech’s Vabysmo Prefilled Syringe (PFS) for Three Leading Causes of Vision Loss
|
|
Jul 5
|
FDA approves Roche’s Vabysmo prefilled syringe (PFS) for three leading causes of vision loss
|
|
Jul 4
|
Roche's (RHHBY) Combo Therapy Misses Lung Cancer Study Goals
|
|
Jul 4
|
Roche’s Phase II/III NSCLC treatment trial fails to meet primary endpoints
|
|
Jul 4
|
Genentech Provides Update on Phase II/III SKYSCRAPER-06 Study in Metastatic Non-Squamous Non-Small Cell Lung Cancer
|
|
Jul 4
|
[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on phase II/III SKYSCRAPER-06 study in metastatic non-squamous non-small cell lung cancer
|
|
Jul 3
|
Roche sues Foresight and Stanford, alleging use of trade secrets
|
|
Jul 1
|
Roche (RHHBY) Gets Positive CHMP Recommendation for Its Drugs
|
|
Jul 1
|
EMA CHMP recommends approval for Roche’s PNH therapy
|
|
Jul 1
|
10 clinical trials to watch in the second half of 2024
|
|
Jun 28
|
Roche’s Vabysmo gets CHMP recommendation for third indication retinal vein occlusion (RVO)
|
|
Jun 28
|
CHMP recommends EU approval of Roche’s PiaSky for people with PNH, a rare, life-threatening blood condition
|
|
Jun 27
|
Roche expands access to cervical cancer screening tools with two new WHO prequalification designations, including HPV self-collection
|
|
Jun 26
|
Pharma M&A: The top high value deals in 2023
|
|
Jun 25
|
Roche's (RHHBY) Ocrevus Subcutaneous Gets European Commission Nod
|
|
Jun 25
|
Roche’s OCREVUS subcutaneous administration approved by European Commission, as first and only twice-a-year injection for relapsing and primary progressive multiple sclerosis
|